Abstract
A Phase II Study to Determine the Safety and Efficacy of the Dual m-TORC Inhibitor AZD2014 and to Investigate Additional Toxicities in Combination with Rituximab in Relapsed/Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
